Brodalumab in psoriatic arthritis (PsA): 24-week results from the phase III AMVISON-1 and -2 trials

Background: The IL-17 receptor blocker brodalumab (BRO) was investigated in PsA in two double-blind, placebo (PBO)-controlled, phase III trials. Although terminated early by sponsor decision, sufficient patients were recruited to allow a meaningful evaluation of efficacy and safety.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research